High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial.

@article{Massard2017HighThroughputGA,
  title={High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial.},
  author={Christophe C Massard and Stefan Michiels and Charles Fert{\'e} and Marie-C{\'e}cile le Deley and Ludovic Lacroix and Antoine Hollebecque and Loic Verlingue and Ecaterina Ileana and Silvia Rosellini and Samy Ammari and Maud Ngo-Camus and Rastislav Bahleda and Anas Gazzah and Andrea J Varga and Sophie Postel-Vinay and Yohann Loriot and Caroline Even and Ingrid Breuskin and Nathalie Auger and Bastien Job and Thierry J de Baere and Fr{\'e}d{\'e}ric J Deschamps and Philippe Vielh and J Y Scoazec and Vladimir Lazar and Catherine Richon and Vincent Ribrag and Eric Deutsch and Eric Angevin and Gilles Vassal and Alexander Eggermont and Fabrice Andr{\'e} and Jean – Charles Soria},
  journal={Cancer discovery},
  year={2017},
  volume={7 6},
  pages={586-595}
}
High-throughput genomic analyses may improve outcomes in patients with advanced cancers. MOSCATO 01 is a prospective clinical trial evaluating the clinical benefit of this approach. Nucleic acids were extracted from fresh-frozen tumor biopsies and analyzed by array comparative genomic hybridization, next-generation sequencing, and RNA sequencing. The primary objective was to evaluate clinical benefit as measured by the percentage of patients presenting progression-free survival (PFS) on matched… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 35 extracted citations

Similar Papers

Loading similar papers…